Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of NXT007 versus factor VIII prophylaxis in hemophilia A without inhibitors
NL-OMON61244Phase 3Recruiting
- Sponsor
- Roche
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of zemocimig and Factor VIII in hemophilia A (2 arms), sponsored by Roche. Primary endpoint: Annualized number of treated bleeds. Started Jul 2026; status: recruiting.
02
Drugs
zemocimigFactor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON61244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61244.